A Study of LY2951742 in Healthy Japanese and Caucasian Participants
| Status: | Completed |
|---|---|
| Conditions: | Migraine Headaches |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 20 - 65 |
| Updated: | 11/8/2014 |
| Start Date: | June 2014 |
| End Date: | January 2015 |
| Contact: | There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or |
| Phone: | 1-317-615-4559 |
A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects
The main purpose of this study is to evaluate the safety of the study drug known as
LY2951742 in healthy Japanese and Caucasians. The study will also investigate how the body
processes the drug and how the drug affects the body. The study is expected to last about 5
to 7 months, depending on the arm.
LY2951742 in healthy Japanese and Caucasians. The study will also investigate how the body
processes the drug and how the drug affects the body. The study is expected to last about 5
to 7 months, depending on the arm.
Inclusion Criteria:
- Participants are either Caucasian or first generation Japanese.
- Participants' body mass index (BMI) is between 18.0 and 35.0 kilogram per meter
square (kg/ m^2).
Exclusion Criteria:
- Participants are heavy caffeine drinkers defined by regular intake of more than 5
cups of coffee (or equivalent in xanthine containing beverages) per day, and/or are
unable or unwilling to abide by caffeine restrictions as specified in the protocol.
- Participants are smoking within the previous 6 months.
- Participants have received treatment with biologic agents (such as monoclonal
antibodies) within 3 months or 5 half-lives (whichever is longer) prior to dosing or
have received a vaccination within 1 month.
- Participants have known allergies to LY2951742, related compounds or any components
of the formulation, or history of significant atopy.
- Participants are allergies to either humanized monoclonal antibodies,
diphenhydramine, epinephrine, or methylprednisolone.
We found this trial at
1
site
Click here to add this to my saved trials
